The Merck Group Website
The Merck Group Website


Rebif® (interferon beta-1a) is a disease modifying drug (DMD) used to treat relapsing forms of multiple sclerosis (MS). It is similar to the interferon beta protein produced by the human body.
Rebif®, which was approved in Europe in 1998 and in the US in 2002, is registered in more than 90 countries worldwide. Rebif® is available in a 22 microgram and 44 microgram ready-to-use pre-filled syringe and a titration pack (8.8 micrograms). Rebif® is also now available in two multidose cartridges for the use with the RebiSmart™ device, in several EU countries, Switzerland and Canada, as well as in Australia.

The information contained in these pages is intended for general reference only. It may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country. This information should not be used to diagnose, treat, cure or prevent any disease without the advice of a qualified medical professional, and does not replace medical advice or a medical examination.

US Residents should consult EMD Serono, Inc. for information on products approved for sale in the United States of America.